Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Preclinical News

Nimbus exposes complete ACLY structure, discovers allosteric inhibitory sites

April 4, 2019 10:30 PM UTC

Nimbus is spinning out a subsidiary to develop ACLY inhibitors targeting a new allosteric site on the enzyme that it discovered in collaboration with Schrödinger and Columbia University.

BioCentury identified lipid biosynthesis regulator ACLY as an emerging metabolic target among abstracts for this year's meeting of the American Association for Cancer Research (AACR) (see "Next-wave Targets at AACR 2019 Start Filling the Blanks in the Tumor Microenvironment")...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article